glp-1 liver fibrosis Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective Frontiers | The mechanisms of

These results were confirmed also in the as-treated analyses (ie, including only those subjects that were persistently on treatment with each drug)

drozdogan.com

On June 10th, researchers from Eli Lilly published findings of a randomized phase 2a clinical trial in "Nature Medicine" titled Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. The study indicated that Retatrutide (LY3437943), a GLP-1R-related triple receptor agonist currently under clinical development, demonstrated significant efficacy and favorable safety in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD)

When the biopsy is obtained partially, the size and appearance of the lesion information that underwent biopsy should be forwarded to the interpreting pathologist or dermatopathologist